A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 270 participants.
Also called NCT06254014
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 270 participants
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Registry
-
NCT06254014
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06254014. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-10 (actual); primary completion 2026-05-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Exendin-4 Fc fusion protein injection
- Intervention (Drug)
- Exendin-4 Fc fusion protein injection
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Dongfang Biotech Co., Ltd.
Record details
- Record id
cardio:ct-nct06254014- Content hash
64d8ef9bbf860e14379dc4b1f466ba6a0488afd81d55f22aad48851a008cce41